Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Investor Presentation (September 2021)
26 slides from Sanara Medtech's investor presentation, Sep 23, 2021
Slide 1: Sanara MedTech Overview
Sanara MedTech Overview (Nasdaq: SMTID September 2021 Sanara MedTech Bvidence Based Healing
Slide 2: Disclaimers
* Sanara = MedTech Disclaimers ‘This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara ‘MedTech ne. (the "Company" “Sanara,” “we,” ‘our’ or us") Al
Slide 3: Company Overview
Company Overview . Sanara MedTech Evidence Based Healing
Slide 4: About Sanara MedTech
About Sanara MedTech With a focus on improving patient outcomes through evidence-based healing technologies, Sanara MedTech Inc. provides products and technologies for surgical and chronic wound care. jhly competitive propriety product portfolio — CellerateRX Surgical Activated Collagen — _BIAKOS An
Slide 5: Comprehensive Wound & Skin Solution for All Care Settings
Comprehensive Wound & Skin Solution for All Care Settings Sanara plans to deliver a comprehensive wound care ecosystem targeting the entire continuum of care, with services expected to drive further product sales and shareholder value All Care Settings i Physician | Inpatient Physician | Clinics and
Slide 6: SMTI Products and Services
SMTI Products and Services ed! MedTech Products Services Wound Care Diagnostics and Virtual Consults ¢%. Sanara CellerateRX® FORTIFY TRG™ Tissue Repair Graft FORTIFY FLOWABLE™ Extracellular Matrix Freeze died mit-yer maltese smucosa (SIS) Advanced wound care device hat prondes the SIS ECM ‘crac ma (
Slide 7: Rochal Technologies (R&D Division)
Rochal Technologies (R&D Division) *. Sanara 3 MedTech Research Team Product Experience Core Capabilities Leader in commercializing technology innovations in wounds, skin care, and burns Ability to manage product development from concept to commercialization 12 employees including 9 scientists/engin
Slide 8: Sanara's Six Wound Care and Surgical Site Therapy Focus Areas
Sanara’s Six Wound Care and Surgical Site Therapy Focus Areas Sanara’s strategy is to create a value proposition through the use of efficacious products and services in the appropriate care settings for wound & skin care Biofilm Removal Hydrolyzed Collagen © Debrider technology licensed and currentl
Slide 9: Surgical and Chronic Wound Disruptive Strategies
Surgical and Chronic Wound Disruptive Strategies Sanara MedTech Bvidence Based Healing
Slide 10: Surgical Wound Disruptive Strategies
Surgical Wound Disruptive Strategies «The industry ne patient clinicz Surgical Wound Market == Future Market Growth © Surgical Wounds are the largest Medicare ‘spend area in wound care totaling $11.78 (including cost of infections)" © 15.3M surgeries in the U.S. each year (excluding ocular surgery),
Slide 11: Wound Care Disruptive Strategies
# Sanara MedTech Wound Care Disruptive Strategies We believe the industry is poised for a disruptive solution to lower costs and improve outcomes Current Wound Care Problem Future Disruptive Solution © Fee-For-Service reimbursement system is antiquated: ‘© Transition to value-based purchasing — Emph
Slide 12: SMTI Surgical Division
SMTI Surgical Division
Slide 13: Surgical Division — Overview
Sanara MedTech Surgical Division — Overview + The surgical division markets and distributes CellerateRX Surgical primarily to hospitals and ambulatory surgical centers (“ASCs”) for use by surgeons in their facilities. = ae | + CellerateRX Surgical is sold through a growing network of independent sur
Slide 14: Surgical Division — Products
Surgical Division — Products *. Sanara 3 MedTech CellerateRX Surgical * CellerateRX Surgical Activated Collagen Powder is composed of medical hydrolysate of Type | bovine collagen that is approximately = 1/100th the size of native collagen Colerte, * CellerateRX Surgical is hydrolyzed collagen that
Slide 15: Cook - Sanara Partnership Products
Cook - Sanara Partnership Products + Executed in December 2020 + Exclusive marketing agreement for Sanara to purchase, market, and distribute three advanced biologics products: — FORTIFY TRG™ Tissue Repair Graft — FORTIFY FLOWABLE™ Extracellular Matrix — VIM™ Amnion Matrix FORTIFY TRG™ Tissue Repair
Slide 16: Surgical Products
Surgical Products Surgical Overview * 26 Regional Sales Managers (“RSMs”) and Territory Sales Managers (“TSMs”) CellerateRX Surgical sold in over 300 hospitals/ASCs as of June 30, 2021 CellerateRX Surgical sold in hospitals/ASCs across 21 states(") as of June 30, 2021 CellerateRX Surgical approved f
Slide 17: SMTI Wound and Virtual Consult Strategy
SMTI Wound and Virtual Consult Strategy Sanara MedTech Evidence Based Heal ing
Slide 18: Wound and Virtual Consult Strategy Overview
Sanara seeks to offer a complete suite of tools to aid clinicians in any care setting as they treat wounds leading to better patient outcomes and lower cost to the healthcare system. The Company’s comprehensive Offering positions it well to target both fee-for-service and value- based/at-risk models
Slide 19: EMR System and Mobile App
Wound tracking analytics Recommended treatment plans/decision support Automated referrals Wound care plan algorithms Efficient revenue cycle workflows Automated and editable progress note development Wound assessment forms that interface with corresponding wound assessment data in providers’ electro
Slide 20: Precision Healing — Investment and Exclusive Use of Technology
Precision Healing — Investment and Exclusive Use Sonarer of Technology wd MedTech Company Overview Retail Opportunity Diagnostic Capabilities + Novel and disruptive approach to multi-billion-dollar unmet need in the Moloouiar Aasey Smart had desdeael care of skin and chronic wounds Quantifies 5-9 ke
Slide 21: Precision Healing Offers the Only Imager to Address Bacteria and Host Response
Precision Healing Offers the Only Imager to ® Sanara Address Bacteria and Host Response MedTech Precision Tissue Healing Moleculight | Wound Vision| HyperMed | SpectralMD Analytics S. Aureus/ Porphyrin <|< & P. Aeruginosa/ Pyoverdine Calor/Heat Granulation NADH’ Cellular Activity Collagen Water! Swe
Slide 22: Wound and Dermatology Virtual Consult Services
» Sanara MedTech Wound and Dermatology Virtual Consult Services Affiliated providers offer: + Ability to provide prompt, cost-effective and scalable virtual care via telemedicine + 48-hour diagnosis (vs. up to six months to get an in-person appointment in some cases for dermatology) Vv) + Ability to
Slide 23: Product Pipeline
Product Pipeline Sanara MedTech Evidence Based Healing
Slide 24: Product Pipeline
‘CuraShield Anti-Microbial Barrier Film + Intended for application ‘on minor wounds and damaged skin as a liquid, film-forming barrier, which creates a ‘waterproof, breathable ‘fim dressing, protecting ‘the wound or damaged skin + Product is biocompatible, non- stinging, and fast drying Description
Slide 25: Financial Performance
Financial Performance . Sanara MedTech Bvidence Based Healing
Slide 26: Q2 2021 Financial Highlights
Q2 2021 Financial Highlights *. Sanara 3 MedTech Overview Revenue Generated $6.3 million in revenue for the three months ended June 30, 2021 versus $3 million for the three months ended June 30, 2020 (112% increase) Generated $11.3 million in revenue for the six months ended June 30, 2021 versus to
Sanara MedTech — Investor Presentation (September 2021) on 6ix